Page 3 - Pharmaceutical Development News Today

How efficacious is brexpiprazole as a treatment for agitation associated with Alzheimer disease?

SWK (NASDAQ:SWKH – Get Free Report) and TROOPS (NASDAQ:TROO – Get Free Report) are both finance companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, dividends, analyst recommendations and earnings. Analyst Recommendations This is a breakdown of recent ratings and […]

SWK (NASDAQ:SWKH – Get Free Report) and TROOPS (NASDAQ:TROO – Get Free Report) are both finance companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, earnings, valuation, analyst recommendations, institutional ownership and profitability. Institutional & Insider Ownership 99.3% of SWK shares are held […]

Pratteln, Switzerland, December 7, 2023 – Santhera Pharmaceuticals (SIX: SANN) announces the promotion of Geert Jan van Daal, MD, PhD, to Chief Commercial Officer (CCO) and of Marc Schrader to Chief Technology Officer (CTO). Both will join the six-member Executive Committee effective January 1, 2024. “Santhera is transitioning to the commercial phase and will make AGAMREE® (vamorolone) available to patients in Europe starting in Germany in early 2024, subject to approval by th...

Conference Call and Live Audio Webcast Scheduled for Thursday, November 9, 2023, at 10:00 a.m. ET Corporate Highlights Third quarter of 2023 GAAP net income...

/PRNewswire/ -- DelNova announces their partnership with Pace® Life Sciences as their intended (CDMO)contract development and manufacturing organization. This...

DelveInsights, Attention Deficit Hyperactivity Disorder Pipeline Insight 2023 report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in the Attention Deficit Hyperactivity...

CHICAGO — At first, Debbie Tumbarello’s wedding was the height of romance — a Valentine’s Day whirlwind straight out of “Sleepless in Seattle,” she said. Tumbarello, who lives in Inverness,

How Gilead’s Pharmaceutical Development and Manufacturing Team Delivers ...

The company's shares rose on signs it might be getting closer to its first biologics license application.